Submicrobial doxycycline and rosacea

Comprehensive Therapy

Volumn 33, Issue 2, 2007, Pages 78-81

  Wise, Ronald D ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CHLORTETRACYCLINE; DOXYCYCLINE; METRONIDAZOLE; MINOCYCLINE; PLACEBO; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

ACNE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE HEPATITIS; BONE GROWTH; BRAIN PSEUDOTUMOR; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONJUNCTIVITIS; DIARRHEA; DISEASE COURSE; DRUG FORMULATION; DRUG MECHANISM; HUMAN; HYPERPIGMENTATION; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOGRANULOMA VENEREUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NONHUMAN; ORNITHOSIS; PERIODONTITIS; PHOTOSENSITIZATION; PREVALENCE; REVIEW; ROSACEA; SIDE EFFECT; TOOTH DISCOLORATION; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG RESISTANCE, BACTERIAL; HUMANS; ROSACEA;

EID: 36949032327     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12019-007-8003-x     Document Type: Review

References (31)

1. Sande MA, Mandell GL. Antimicrobial agents. In: Gilman, AG, Rall, TW, Nies, AS, Taylor, P, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. McGraw-Hill; 1993. p.1117-25.
2. Meyers B, Salvatore M. Tetracyclines and chloramphenicol. In: Mandell Gl, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia, PA: Elsevier; 2005. p. 357-66.
3. Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: Mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992;5(4):38-99.
4. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. SKINmed 2003;2(4):234-45, Review.
5. Baldwin HE. Oral therapy for rosacea. J Drugs Dermatol 2006;5(1):16-21.
6. Levy SB. The challenge of antibiotic resistance. Sci Am 1998;278(3):46-53.
7. Bernstein JM. Treatment of community-acquired pneumonia-IDSA guidelines. Chest 1999;1115:95-135.
8. Stanford Hospital & Clinics. Antibiotic susceptibility of bacteria and yeasts. Available at: http://med.stanford.edu/lane/schid/susceptibility/ ReportB.htm. (Accessed February 10, 2006).
9. US Food and Drug Administration. FDA publishes final rule to require labeling about antibiotic resistance. FDA News. Available at: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00869.html. (Accessed February 10, 2006).
10. Powell FC. Rosacea. N Engl J Med 2005;352(8):793-803.
11. National Rosacea Society. 14 million Americans urged to face up to rosacea before it gets worse. News Releases. April; 1, 2005. Available at: http://www.rosacea.org/press/archive/20050401.html. (Accessed February 10, 2006).
12. Milliklin L. The proposed inflammatory pathophysiology of rosacea: Implications for treatment. SKINmed 2003;2(1):43-7.
13. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venerol 1989;69(5):419-23.
14. Wilkin J, Dahl M, Detmar M. et al. Standard classification of rosacea. Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2004;50(6):907-12.
15. Crawford GH, Pelle MT, James, WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004;51(3):327-41.
16. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea. Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002;46(4):584-87.
17. Jansen T, Plewig GJ. Rosacea: classification and treatment. R Soc Med 1997;90(3):144-50.
18. Buechner SA. Rosacea: An update. Dermatology 2005;201(2):100-8.
19. Bikowski JB. What you should know about subantimicrobial dose doxycycline. Pract Dermatol 2005;2(6):38-43.
20. Jones D. Reactive oxygen species and rosacea. Cutis 2004;74(Suppl 3):17-20, Review.
21. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: Implications for rosacea management. Adv Ther 2001;18(6):237-43.
22. Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966;78(12):649-52.
23. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54(2):258-65.
24. Del Russo JQ. The antibiotic paradox: benefits and risks of using antimicrobial oral antibiotics for the systemic treatment of rosacea. Cutis 2004;74(2):118-22.
25. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12(2):12-26.
26. Schroeder K, Lee H, Wolff M, et al. Low-dose tetracyclines (TCs) decrease elastase and beta-glucuronidase activities in gingival crevicular fluid (GCF) [abstract 1090]. J Dent Res 1990;69(special issue):245.
27. Schroeder KL, Ramamurphy NS, Szczepanek KA, et al. Low-dose tetracycline prevents attachment loss in adult periodontitis [abstract 1936]. J Dent Res 1992;71:758.
28. Skidmore R, Kovach R, Walker C, et al. Effects of submicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003;39(4):459-64.
29. Del Rosso JQ, Bikowski J. When is an antibiotic not an antibiotic? Skin & Aging. 2004;11:36-42.
30. Golub LM, Wolff M, Roberts S, et al. Treating periodontal diseases by blocking tissue-destructive enzymes. J Am Dent Assoc 1994;125:163-69 (discussion 169-71).
31. Oracea. Newtown, PA: CollaGenex Pharmaceuticals; 2006 (prescribing information).